GLP-1 agonists are typically prescribed to adults over the age of 18 who are overweight or obese with a body mass index (BMI) above 30
Association with inhibition of gastric acid secretion in humans
In Summary Like everything in diabetes, there is not a one-size-fits-all approach
This week is about showing up and getting comfortable, not setting records
Practical Considerations for Taking Empagliflozin Empagliflozin, a leading medication for type 2 diabetes, requires attention to detail in terms of dosing, administration, and lifestyle considerations to ensure effectiveness and safety
These results follow similar findings from the companys ATTAIN-1 trial released earlier this month, which tested the drug on people who were overweight or obese without type 2 diabetes (in general, people without diabetes tend to lose more weight from GLP-1 therapy than those with diabetes)